US-based biopharmaceutical company Kashiv Biosciences has reported that a Phase I trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary endpoints.

In the trial, the abatacept biosimilar candidate KSHB002 showed pharmacokinetic equivalence to the reference product, Orencia.

The randomised, open-label study enrolled 300 healthy adult male and female subjects and was divided into three parallel arms.

It aimed to evaluate the injection’s safety, immunogenicity and pharmacokinetics against Orencia, with all subjects receiving a subcutaneous dose.

According to the trial findings, the primary endpoints, maximum serum concentration (Cmax) and area under the concentration-time curve from time zero to infinity (AUC₀–∞) all fell within the bioequivalence range of 80%-125%.

In addition, the biosimilar’s safety and immunogenicity profiles were comparable to those of the reference product.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Enter your work email
First Name
Last Name
Company Name
Job title *
Phone number *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kashiv Biosciences is currently developing subcutaneous and intravenous formulations of the injection.

Kashiv Biosciences CEO Dr Sandeep Athalye said: “We are thrilled with the results of our Phase I study and are excited to move forward with our global Phase III efficacy and safety trial.

“This represents a pivotal step in advancing the evaluation of KSHB002 for patients with rheumatoid arthritis.”

Kashiv Biosciences provides global research and development, manufacturing, clinical, regulatory and intellectual property capabilities to advance patient care and expand access to affordable essential medicines.

Based in New Jersey, the company operates in India and the US, with a focus on delivering a portfolio of commercial and clinical-stage assets.

In July 2024, Kashiv Biosciences finished enrolling subjects in a Phase III study of ADL018, a biosimilar to Xolair.

The study enrolled 600 subjects worldwide and aims to assess the biosimilar’s efficacy in chronic idiopathic/spontaneous urticaria treatment in subjects who are symptomatic despite H1 antagonist treatment.

In the same month, the company entered an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialisation of ADL018 in the US.